Clinical trials-major depression venlafaxine or bupropion responders but not nonresponders show baseline prefrontal and paralimbic hypometabolism compared with controls

Psychopharmacology Bulletin

Volumn 32, Issue 4, 1996, Pages 629-635

  Little, John T ^a  

^a NATIONAL INSTITUTE OF MENTAL HEALTH   (United States)

Author keywords

Bupropion; Cerebral glucose metabolism; Depression; Positron emission tomography; Venlafaxine

Indexed keywords

AMFEBUTAMONE; ANTIDEPRESSANT AGENT; FLUORODEOXYGLUCOSE F 18; VENLAFAXINE;

ADULT; BRAIN METABOLISM; CLINICAL ARTICLE; CLINICAL TRIAL; CONFERENCE PAPER; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CROSSOVER PROCEDURE; DEPRESSION; DOUBLE BLIND PROCEDURE; FEMALE; GLUCOSE METABOLISM; HUMAN; LIMBIC CORTEX; MALE; POSITRON EMISSION TOMOGRAPHY; PREFRONTAL CORTEX; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RATING SCALE;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; CEREBROVASCULAR CIRCULATION; CYCLOHEXANOLS; DEPRESSIVE DISORDER; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MALE; MIDDLE AGED; PREFRONTAL CORTEX; TOMOGRAPHY, EMISSION-COMPUTED;

EID: 0030468201     PISSN: 00485764     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (1)

1. Ascher, JA; Cole, JO; Colin, JN; Feighner, JP; Ferris, RM; Fibiger, HC; Golden, RN; Martin, P; Potter, WZ; Richelson, E; and Sulser, F. Bupropion: A review of its mechanism of antidepressant activity. J. Clin. Psychiatry 56:395-401, 1995.